<p>Corvus Pharmaceuticals（纳斯达克代码：CRVS - 获取免费报告）在华尔街 Zen 的投资分析师的研究报告中，将其评级从 “卖出” 上调至 “持有”。</p>
<p>获取 <strong>Corvus Pharmaceuticals</strong> 的提醒：</p>
<p>其他几位研究分析师最近也对 CRVS 发布了报告。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Corvus Pharmaceuticals 股票的 “卖出（d-）” 评级。瑞穗证券在 10 月 29 日的研究报告中对 Corvus Pharmaceuticals 的股票设定了 13.00 美元的目标价。最后，巴克莱在 10 月 13 日的研究报告中开始覆盖 Corvus Pharmaceuticals 的股票。他们对该股票设定了 “增持” 评级和 16.00 美元的目标价。四位投资分析师对该股票给予了买入评级，一位分析师则给予了卖出评级。根据 MarketBeat.com 的数据，Corvus Pharmaceuticals 目前的平均评级为 “适度买入”，平均目标价为 14.25 美元。</p>
<p><strong>查看我们关于 CRVS 的最新报告</strong></p>
<h2>Corvus Pharmaceuticals 价格表现</h2>
<p>CRVS 的股票在周五开盘价为 7.60 美元。该公司的市值为 5.6757 亿美元，市盈率为-14.34，贝塔值为 0.56。Corvus Pharmaceuticals 的股价在过去一年内最低为 2.54 美元，最高为 10.00 美元。该公司的 50 日简单移动平均线为 6.84 美元，200 日简单移动平均线为 5.10 美元。</p>
<p>Corvus Pharmaceuticals（纳斯达克代码：CRVS - 获取免费报告）最近在 11 月 4 日发布了季度财报。该公司报告每股收益（EPS）为-0.12 美元，超出市场共识预期的-0.14 美元，超出幅度为 0.02 美元。平均而言，卖方分析师预计 Corvus Pharmaceuticals 在当前财政年度的每股收益为-0.63 美元。</p>
<h2>Corvus Pharmaceuticals 的机构交易</h2>
<p>机构投资者和对冲基金最近对该公司的持仓进行了调整。Towerview LLC 在第一季度将其在 Corvus Pharmaceuticals 的股份增加了 64.5%。Towerview LLC 目前拥有 127,500 股该公司的股票，价值 405,000 美元，在此期间又购买了 50,000 股。美国世纪公司在第一季度将其在 Corvus Pharmaceuticals 的持股增加了 103.9%。美国世纪公司目前拥有 89,265 股该公司的股票，价值 284,000 美元，在上个季度又购买了 45,491 股。威灵顿管理集团在第一季度获得了 Corvus Pharmaceuticals 的新头寸，价值约为 333,000 美元。Jump Financial LLC 在第一季度购买了 Corvus Pharmaceuticals 的新股份，价值约为 143,000 美元。最后，OMERS ADMINISTRATION Corp 在第一季度将其在 Corvus Pharmaceuticals 的股份增加了 9.0%。OMERS ADMINISTRATION Corp 目前拥有 82,300 股该公司的股票，价值 262,000 美元，在上个季度又购买了 6,800 股。机构投资者持有该公司 46.64% 的股份。</p>
<h2>Corvus Pharmaceuticals 公司简介</h2>
<p>（获取免费报告）</p>
<p>Corvus Pharmaceuticals, Inc 是一家临床阶段的生物制药公司，专注于开发和商业化免疫调节剂产品候选药物，以治疗实体癌症、T 细胞淋巴瘤、自身免疫性疾病、过敏性疾病和传染病。其主要产品候选药物是 soquelitinib（CPI-818），这是一种选择性共价抑制剂，针对白细胞介素 2 诱导的 T 细胞激酶（ITK），目前正在进行多中心的 1/1b 期临床试验，以治疗外周 T 细胞淋巴瘤、实体肿瘤和特应性皮炎。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票，胜过 Corvus Pharmaceuticals</li>
<li>如何计算投资回报率（ROI）</li>
<li>OpenAI 的重组可能会成为有史以来最大的 IPO</li>
<li>消费者可选消费股票解析</li>
<li>美国政府不希望失败的两只稀土股票</li>
<li>什么是股息之王？</li>
<li>CrowdStrike 与 CoreWeave 合作，但投资者抛售消息</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JWUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JWUw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Corvus Pharmaceuticals 吗？</h2>
<p>在你考虑投资 Corvus Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前……而 Corvus Pharmaceuticals 并不在名单上。</p>
<p>虽然 Corvus Pharmaceuticals 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Corvus制药

<p>华尔街禅在最近的一份报告中将 Corvus Pharmaceuticals（NASDAQ:CRVS）的评级从 “卖出” 上调至 “持有”。其他分析师的观点各异，Weiss Ratings 维持 “卖出” 评级，而巴克莱则给予 “增持” 评级，目标价为 16.00 美元。Corvus 的市值为 5.6757 亿美元，报告的每股收益为（0.12 美元），超出预期。机构投资者持有该股票的 46.64%，当前价格为 7.60 美元，过去一年的价格区间为 2.54 美元至 10.00 美元</p>

<p>Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note issued on Saturday.</p>
<div class="lb-trans"><p>Corvus Pharmaceuticals（纳斯达克代码：CRVS - 获取免费报告）在华尔街 Zen 的投资分析师的研究报告中，将其评级从 “卖出” 上调至 “持有”。</p>
</div><p>Get <strong>Corvus Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Corvus Pharmaceuticals</strong> 的提醒：</p>
</div><p>Several other research analysts also recently issued reports on CRVS. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Corvus Pharmaceuticals in a research report on Wednesday, October 8th. Mizuho set a $13.00 target price on shares of Corvus Pharmaceuticals in a research note on Wednesday, October 29th. Finally, Barclays assumed coverage on shares of Corvus Pharmaceuticals in a research note on Monday, October 13th. They set an &#34;overweight&#34; rating and a $16.00 price target on the stock. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Corvus Pharmaceuticals presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $14.25.</p>
<div class="lb-trans"><p>其他几位研究分析师最近也对 CRVS 发布了报告。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Corvus Pharmaceuticals 股票的 “卖出（d-）” 评级。瑞穗证券在 10 月 29 日的研究报告中对 Corvus Pharmaceuticals 的股票设定了 13.00 美元的目标价。最后，巴克莱在 10 月 13 日的研究报告中开始覆盖 Corvus Pharmaceuticals 的股票。他们对该股票设定了 “增持” 评级和 16.00 美元的目标价。四位投资分析师对该股票给予了买入评级，一位分析师则给予了卖出评级。根据 MarketBeat.com 的数据，Corvus Pharmaceuticals 目前的平均评级为 “适度买入”，平均目标价为 14.25 美元。</p>
</div><p><strong>View Our Latest Report on CRVS</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 CRVS 的最新报告</strong></p>
</div><h2>Corvus Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Corvus Pharmaceuticals 价格表现</h2>
</div><p>Shares of CRVS opened at $7.60 on Friday. The company has a market capitalization of $567.57 million, a P/E ratio of -14.34 and a beta of 0.56. Corvus Pharmaceuticals has a one year low of $2.54 and a one year high of $10.00. The business's 50 day simple moving average is $6.84 and its 200-day simple moving average is $5.10.</p>
<div class="lb-trans"><p>CRVS 的股票在周五开盘价为 7.60 美元。该公司的市值为 5.6757 亿美元，市盈率为-14.34，贝塔值为 0.56。Corvus Pharmaceuticals 的股价在过去一年内最低为 2.54 美元，最高为 10.00 美元。该公司的 50 日简单移动平均线为 6.84 美元，200 日简单移动平均线为 5.10 美元。</p>
</div><p>Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.02. On average, sell-side analysts anticipate that Corvus Pharmaceuticals will post -0.63 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Corvus Pharmaceuticals（纳斯达克代码：CRVS - 获取免费报告）最近在 11 月 4 日发布了季度财报。该公司报告每股收益（EPS）为-0.12 美元，超出市场共识预期的-0.14 美元，超出幅度为 0.02 美元。平均而言，卖方分析师预计 Corvus Pharmaceuticals 在当前财政年度的每股收益为-0.63 美元。</p>
</div><h2>Institutional Trading of Corvus Pharmaceuticals</h2>
<div class="lb-trans"><h2>Corvus Pharmaceuticals 的机构交易</h2>
</div><p>Institutional investors and hedge funds have recently made changes to their positions in the business. Towerview LLC grew its stake in shares of Corvus Pharmaceuticals by 64.5% during the first quarter. Towerview LLC now owns 127,500 shares of the company's stock worth $405,000 after purchasing an additional 50,000 shares during the period. American Century Companies Inc. boosted its holdings in Corvus Pharmaceuticals by 103.9% during the first quarter. American Century Companies Inc. now owns 89,265 shares of the company's stock worth $284,000 after buying an additional 45,491 shares during the last quarter. Wellington Management Group LLP acquired a new position in shares of Corvus Pharmaceuticals during the 1st quarter worth about $333,000. Jump Financial LLC bought a new stake in shares of Corvus Pharmaceuticals in the 1st quarter valued at about $143,000. Finally, OMERS ADMINISTRATION Corp increased its stake in shares of Corvus Pharmaceuticals by 9.0% in the 1st quarter. OMERS ADMINISTRATION Corp now owns 82,300 shares of the company's stock valued at $262,000 after acquiring an additional 6,800 shares during the last quarter. Institutional investors own 46.64% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近对该公司的持仓进行了调整。Towerview LLC 在第一季度将其在 Corvus Pharmaceuticals 的股份增加了 64.5%。Towerview LLC 目前拥有 127,500 股该公司的股票，价值 405,000 美元，在此期间又购买了 50,000 股。美国世纪公司在第一季度将其在 Corvus Pharmaceuticals 的持股增加了 103.9%。美国世纪公司目前拥有 89,265 股该公司的股票，价值 284,000 美元，在上个季度又购买了 45,491 股。威灵顿管理集团在第一季度获得了 Corvus Pharmaceuticals 的新头寸，价值约为 333,000 美元。Jump Financial LLC 在第一季度购买了 Corvus Pharmaceuticals 的新股份，价值约为 143,000 美元。最后，OMERS ADMINISTRATION Corp 在第一季度将其在 Corvus Pharmaceuticals 的股份增加了 9.0%。OMERS ADMINISTRATION Corp 目前拥有 82,300 股该公司的股票，价值 262,000 美元，在上个季度又购买了 6,800 股。机构投资者持有该公司 46.64% 的股份。</p>
</div><h2>Corvus Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Corvus Pharmaceuticals 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.</p>
<div class="lb-trans"><p>Corvus Pharmaceuticals, Inc 是一家临床阶段的生物制药公司，专注于开发和商业化免疫调节剂产品候选药物，以治疗实体癌症、T 细胞淋巴瘤、自身免疫性疾病、过敏性疾病和传染病。其主要产品候选药物是 soquelitinib（CPI-818），这是一种选择性共价抑制剂，针对白细胞介素 2 诱导的 T 细胞激酶（ITK），目前正在进行多中心的 1/1b 期临床试验，以治疗外周 T 细胞淋巴瘤、实体肿瘤和特应性皮炎。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Corvus Pharmaceuticals</li>
<li>How to Calculate Return on Investment (ROI)</li>
<li>OpenAI's Restructuring Sets up What Could Be the Biggest IPO Ever</li>
<li>Consumer Discretionary Stocks Explained</li>
<li>2 Rare Earth Stocks the U.S. Government Doesn’t Want to Fail</li>
<li>What is a Dividend King?</li>
<li>CrowdStrike Partners With CoreWeave But Investors Sell the News</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Corvus Pharmaceuticals</li>
<li>如何计算投资回报率（ROI）</li>
<li>OpenAI 的重组可能会成为有史以来最大的 IPO</li>
<li>消费者可选消费股票解析</li>
<li>美国政府不希望失败的两只稀土股票</li>
<li>什么是股息之王？</li>
<li>CrowdStrike 与 CoreWeave 合作，但投资者抛售消息</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JWUw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=CRVS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Corvus Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Corvus Pharmaceuticals 吗？</h2>
</div><p>Before you consider Corvus Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑投资 Corvus Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corvus Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前……而 Corvus Pharmaceuticals 并不在名单上。</p>
</div><p>While Corvus Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Corvus Pharmaceuticals 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

华尔街禅将 Corvus 制药（NASDAQ:CRVS）的评级上调至 “持有”